Abstract:Infectious diseases are a major cause for morbidity and mortality in the older population. Demographic changes will lead to increasing numbers of older persons over the next decades. Prevention of infections becomes increasingly important to ensure healthy aging for the individual, and to alleviate the socio-economic burden for societies. Undoubtedly, vaccines are the most efficient health care measure to prevent infections. Age-associated changes of the immune system are responsible for decreased immunogenicity and clinical efficacy of most currently used vaccines in older age. Efficacy of standard influenza vaccines is only 30–50% in the older population. Several approaches, such as higher antigen dose, use of MF59 as adjuvant and intradermal administration have been implemented in order to specifically target the aged immune system. The use of a 23-valent polysaccharide vaccine against <i>Streptococcus pneumoniae</i> has been amended by a 13-valent conjugated pneumococcal vaccine originally developed for young children several years ago to overcome at least some of the limitations of the T cell-independent polysaccharide antigens, but still is only approximately 50% protective against pneumonia. A live-attenuated vaccine against herpes zoster, which has been available for several years, demonstrated efficacy of 51% against herpes zoster and 67% against post-herpetic neuralgia. Protection was lower in the very old and decreased several years after vaccination. Recently, a recombinant vaccine containing the viral glycoprotein gE and the novel adjuvant AS01B has been licensed. Phase III studies demonstrated efficacy against herpes zoster of approx. 90% even in the oldest age groups after administration of two doses and many countries now recommend the preferential use of this vaccine. There are still many infectious diseases causing substantial morbidity in the older population, for which no vaccines are available so far. Extensive research is ongoing to develop vaccines against novel targets with several vaccine candidates already being clinically tested, which have the potential to substantially reduce health care costs and to save many lives. In addition to the development of novel and improved vaccines, which specifically target the aged immune system, it is also important to improve uptake of the existing vaccines in order to protect the vulnerable, older population.

How Can We Improve Vaccination Response in Old People? Part I: Targeting Immunosenescence of Innate Immunity Cells

Targeting Inflammation and Immunosenescence to Improve Vaccine Responses in the Elderly

Insights into Vaccines for Elderly Individuals: from the Impacts of Immunosenescence to Delivery Strategies

Novel Technologies to Improve Vaccines for Older Adults

Immunosenescence and Its Hallmarks: How to Oppose Aging Strategically? A Review of Potential Options for Therapeutic Intervention

Vaccines to Prevent Infectious Diseases in the Older Population: Immunological Challenges and Future Perspectives

Enhancing vaccine effectiveness in the elderly to counter antibiotic resistance: The potential of adjuvants via pattern recognition receptors

Vaccination for healthy aging

Vaccination programs for older adults in an era of demographic change

A silver bullet for ageing medicine?: clinical relevance of T-cell checkpoint receptors in normal human ageing

Optimising vaccine immunogenicity in ageing populations: key strategies

Aging of the immune system: Focus on inflammation and vaccination

Systemic dysregulation and molecular insights into poor influenza vaccine response in the aging population

Human innate immunosenescence: causes and consequences for immunity in old age

The Prevention of Infections in Older Adults: Vaccination

Aging and Microbiome in the Modulation of Vaccine Efficacy

Novel nanoadjuvants balance immune activation with modest inflammation: implications for older adult vaccines

The Impact of Immune System Aging on Infectious Diseases

The 3 I’s of immunity and aging: immunosenescence, inflammaging, and immune resilience

Sexual-Dimorphism In Human Immune System Aging

Vaccines for the Elderly and Vaccination Programs in Europe and the United States